Baltimore Business JournalFast-growing Frederick stem cell manufacturer raises $6 millionBaltimore Business JournalTraditionally, stem cells batches used in a clinical trial can take weeks or months to generate. RoosterBio aims to to accelerate that pr… Continue reading
Scope (blog) |
“The tip of the iceberg”: A look at stem cell science at Stanford
Scope (blog) The piece introduces the pioneering work of Irving Weissman, MD, who was the first researcher to isolate stem cells from adult tissue. And it highlights the amazing outcome from a recent clinic trial on stem cell therapy for stroke led by neurosurgeon … |
Proactive Investors Australia |
Stemcell United shares fly on medicinal cannabis plan
Proactive Investors Australia Stemcell United (ASX:SCU) has appointed medicinal cannabis expert Nevil Schoenmakers as strategic advisor to assist the company in assessing opportunities in the medicinal cannabis sector. The company’s shares were last trading 3054% higher intra-day … |
Investopedia |
CRISPR and MaxCyte In Cell Engineering Pact (CRSP)
Investopedia and Casebia Therapeutics Inc. are partnering with privately-held MaxCyte Inc. for the non-exclusive commercial rights to MaxCyte’s cell engineering platform to develop CRISPR/Cas9-based therapies. (See also, The Gene-Editing Revolution: What Is … |
Curetoday.com |
What’s Next for Immunotherapy and Targeted Therapy in Lung Cancer?
Curetoday.com There is specific scientific rationale to support the combination of chemotherapy with immunotherapy, and there is a large body of literature suggesting that these combinations may be beneficial. The final judgment will be made by the FDA, but this … |
MedCity News |
Allergan and Editas announce $90M CRISPR deal
MedCity News Of note, Allergan has scooped up licenses pertaining to both CRISPR/Cas9 and CRISPR/Cpf1. The latter was developed through the work of Feng Zhang and collaborators at the Broad Institute, MIT and Harvard — the institutions that Editas licenses its … Allergan and Editas Medicine Enter into Strategic R&D Alliance to …P&T Community Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing …Yahoo Finance Editas, Allergan Ink $90M CRISPR-Based Eye Drug DealGenomeWeb Pharmaceutical Executive (press release) (registration) (blog) all 34 news articles » |